Treatment of high baseline viral load chronic hepatitis B using sequential therapy with entecavir and PEG-IFN

Background: The HBeAg-positive chronic hepatitis B is the type of chronic hepatitis with active virus replication, has high viral load and difficult to treat. We evaluate the effects of treatment with tenofovir in HBeAg-positive chronic hepatitis B patients. Aims: Evaluate the treatment results in patients with HBeAg-positive chronic hepatitis B. Patients and methodes: HBeAg-positive chronic hepatitis B patients over 15 yrs treated at Hue University Hospital from Jan. 2012 to Dec. 2013. Results: Most of symptoms disappeared after 12 months. More than 85% patients have biochemical response. 81.8% patients have undetectable HBV DNA. Rate of HBV DNA decrease according to the baseline viral load. After 12 months 27.3% patients loss HBeAg and 20.5% have anti-HBe. Conclusions: Clinical and biochemical response were relatively high. 81.8% patients have undetectable HBV DNA. After 12 months 27.3% patients loss HBeAg and 20.5% have anti-HBe. Key words: HBeAg-positive chronic hepatitis B, HBV DNA

Download Full-text

Detection of Hepatitis B Genotypes in HBsAg & HBeAg Carriers

Journal of Biomedical and Pharmaceutical Research ◽

10.32553/jbpr.v7i5.556 ◽

2018 ◽

Vol 7 (5) ◽

Author(s):

Salman Khan ◽

Molly Madan

Keyword(s):

Chronic Hepatitis ◽

Viral Load ◽

Hepatitis B Virus ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Central Research ◽

Elisa Kit ◽

B Virus ◽

Negative Chronic Hepatitis ◽

Genotype A

Objective:- Hepatitis B is noteworthy medical issues that may include the late continuation of liver cirrhosis and hepatocellular carcinoma. The present study aimed for the detection and diffrentiation of Hepatitis B virus HBsAg inactive non-replicative carriers, HBeAg-positive inactive replicative carriers, active carriers & HBeAg-negative chronic hepatitis B by Real Time PCR and their genotyping Methods: This research conducted on 245 positive for HBsAg, 118 (48.16 %) were male and 127 (51.84%) were female patients, which was performed in central research station labortory of Microbiology at netaji subhash Chandra Bose subharti Medical College and Hospital, Meerut Between march 2016 to November 2017 The sera were separated and screened for HBsAg by ELISA kit. Positive samples for HBsAg were tested for HBeAg ELISA kit and DNA Viral load then sequenced for genotying Results:. Of the 245 HBsAg Positive case 55 (1.12%) were HBeAg positive. In 16 PCR positive and HBV genotyping, In HBsAg inactive Non-Replicative 37.5% (n=6) genotype-B and 6.25% (n=1) genotype-A, In HBeAg inactive Replicative 12.5% (n=2) genotype-B and 12.5% (n=2) genotype-A and In HBeAg Active Chronic Hepatitis B 18.75% (n=3) genotype-B and 12.5% (n=2) genotype-A were detected Conclusions: Management strategy, using HBsAg, HBeAg and HBV DNA viral load, seems adequate for the confirmation and diffrentiation of Hepatitis B virus inactive, active carriers & HBeAg-negative chronic hepatitis B patients and genotype B was more prevalent in comparission to genotype A. Distribution of carriers & genotypes, help physicians to prescribe proper antiviral/interferon therapy according to current genotyping pattern in this region Keywords: Hepatitis B virus, Carrier State, HBsAg, HBeAg, RT-PCR

Download Full-text

Update in management of hepatitis B in pregnancy and prevention of mother to child hepatitis B transmission

Thai Journal of Hepatology ◽

10.30856/th.jhep2018vol1iss3_01 ◽

2018 ◽

Vol 1 (3) ◽

pp. 1-8

Author(s):

Naichaya Chamroonkul

Keyword(s):

Chronic Hepatitis ◽

Viral Load ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

High Viral Load ◽

World Population ◽

Hepatitis B Infection ◽

Mother To Child Transmission ◽

Child Transmission ◽

Mother To Child

Even with two decades of widespread using hepatitis B vaccination, chronic hepatitis B remains a major global health problem. In Thailand, the prevalence of chronic hepatitis B infection was down from 8 - 10% in last decade to 5% recently. Failure to control mother to child transmission is one of the important barriers to the total elimination of hepatitis B infection from world population. In the majority, vertical transmission can be prevented with a universal screening program, immunoprophylaxis by administration of hepatitis B vaccine and hepatitis B immunoglobulin (HBIg) for babies born to mothers with HBV. However, in mothers with a high viral load, the chance of immunoprophylaxis failure remains high. To date, there are standard recommendations by all international liver societies including AASLD, EASL and APASL suggest introducing an antiviral agent during the third trimester to CHB pregnant women with a high viral load. Previous US FDA pregnancy category B agents such as Tenofovir and Telbivudine are allowed through all trimesters of pregnancy and are effective for prevention of mother to child transmission. Breastfeeding for patients who receive antiviral agents can be allowed after a risk-benefit discussion with the patient and family.

Download Full-text